Doing what I like

Annual Review of Immunology

Volumn 26, Issue , 2008, Pages 1-28

  Austen, K Frank ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alternative complement pathway; Cysteinyl leukotrienes; Mast cell; Mast cell progenitors; Slow reacting substance of anaphylaxis

Indexed keywords

7 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY) 2 HYDROXYPROPOXY] 4 OXO 8 PROPYL 4H 1 BENZOPYRAN 2 CARBOXYLIC ACID; ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; BRADYKININ; CARBOXYPEPTIDASE A; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CROMOGLYCATE DISODIUM; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E; LEUKOTRIENE A4; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE D4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR; LIPOPOLYSACCHARIDE; PEPTIDOLEUKOTRIENE; PROPERDIN; PROSTAGLANDIN D2; PROSTAGLANDIN F2 ALPHA; PROTEINASE; PROTEOGLYCAN; SLOW REACTING SUBSTANCE;

ALLERGIC RHINITIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTHRITIS; ASTHMA; CAREER PLANNING; CELL FUNCTION; CELLULAR DISTRIBUTION; COMBINATION CHEMOTHERAPY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG MEGADOSE; HISTAMINE RELEASE; HUMAN; HYPOTENSION; LOW DRUG DOSE; MAST CELL; MEDICAL EDUCATION; MEDICAL PRACTICE; MEDICAL RESEARCH; MUTAGENESIS; NONHUMAN; NOTE; POLIOMYELITIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SECRETORY GRANULE; SIGNAL TRANSDUCTION; SYSTEMIC MASTOCYTOSIS; WILD TYPE; X RAY CRYSTALLOGRAPHY;

ALLERGY AND IMMUNOLOGY; ANDROSTANOLS; ANGIOEDEMA, HEREDITARY; ANTIGENS, CD55; AUTOBIOGRAPHY; BRONCHOCONSTRICTION; COMPLEMENT ACTIVATION; COMPLEMENT PATHWAY, ALTERNATIVE; CROMOLYN SODIUM; HEMOGLOBINURIA, PAROXYSMAL; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; MAST CELLS; PORTRAITS AS TOPIC; PROSTAGLANDIN D2; RECEPTORS, LEUKOTRIENE; SRS-A; STEM CELLS; UNITED STATES;

EID: 42649087084     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.26.021607.090339     Document Type: Note

References (131)

1. Austen KF. 1978. Homeostasis of effector systems which can also be recruited for immunologic reactions. Pres. Address Am. Assoc. Immunol. J. Immunol. 121:793-805
2. Austen KF, Koch-Weser J, Field RA. 1956. Cardiorespiratory problems in severe poliomyelitis observed during the recent epidemic. N. Engl. J. Med. 254:790-93
3. Drazen JM. 2004. Presentation of the Kober Medal to K. Frank Austen. J. Clin. Invest. 114:1174-76
4. Livingstone JB, Austen KF, Kunz LJ. 1957. A study of intercurrent bacterial respiratory infections in bulbospinal poliomyelitis. N. Engl. J. Med. 257:861-66
5. Austen KF, Carmichael MW, Adams RD. 1957. Neurologic manifestations of chronic pulmonary insufficiency. N. Engl. J. Med. 257:579-90
6. Austen KF, Rubini ME, Meroney WH, Wolff J. 1958. Salicylates and thyroid function. I. Depression of thyroid function. J. Clin. Invest. 37:1131-43
7. Wolff J, Austen KF. 1958. Salicylates and thyroid function. II. The effect on the thyroid-pituitary interrelation. J. Clin. Invest. 37:1144-52
8. Austen KF. 1960. The differentiation of the chloroform, peptone and antigen antibody inducible esterase activities of human serum from plasmin. Immunology 3:152-73
9. Austen KF, Brocklehurst WE. 1961. Anaphylaxis in chopped guinea pig lung. I. Effect of peptidase substrates and inhibitors. J. Exp. Med. 113:521-39
10. Austen KF, Brocklehurst WE. 1961. Anaphylaxis in chopped guinea pig lung. II. Enhancement of the anaphylactic release of histamine and slow reacting substance by certain dibasic aliphatic acids and inhibition by monobasic fatty acids. J. Exp. Med. 113:541-57
11. Austen KF, Brocklehurst WE. 1961. Anaphylaxis in chopped guinea pig lung. III. Effect of carbon monoxide, cyanide, salicylaldoxine, and ionic strength. J. Exp. Med. 114:29-42
12. Humphrey JH, Austen KF, Rapp HJ. 1963. In vitro studies of reversed anaphylaxis with rat cells. Immunology 6:226-45
13. Stroud RM, Austen KF, Mayer MM. 1965. Catalysis of C'2 fixation by C'1a: reaction kinetics, competitive inhibition by TAMe, and transferase hypothesis of the enzymatic action of C'1a on C'2, one of its natural substrates. Immunochemistry 2:219-34
14. Murphy RC, Hammarstrom S, Samuelsson B. 1979. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc. Natl. Acad. Sci. USA 76:4275-79
15. Stechschulte DJ, Austen KF, Bloch KJ. 1967. Antibodies involved in antigen-induced release of slow reacting substance of anaphylaxis (SRS-A) in the guinea pig and rat. J. Exp. Med. 125:127-47
16. Orange RP, Stechschulte DJ, Austen KF. 1970. Immunochemical and biologic properties of rat IgE. II. Capacity to mediate the immunologic release of histamine and slow reacting substance of anaphylaxis (SRS-A). J. Immunol. 105:1087-95
17. Ishizaka T, Ishizaka K, Orange RP, Austen KF. 1970. The capacity of human immunoglobulin E to mediate the release of histamine and slow reacting substance of anaphylaxis (SRS-A) from monkey lung. J. Immunol. 104:335-43
18. rat): association of this activity with rat IgGa. J. Immunol. 101:658-63
19. Orange RP, Murphy RC, Karnovsky ML, Austen KF. 1973. The physicochemical characteristics and purification of slow reacting substance of anaphylaxis. J. Immunol. 110:760-70
20. Orange RP, Murphy RC, Austen KF. 1974. Inactivation of slow reacting substance of anaphylaxis (SRS-A) by arylsulfatases. J. Immunol. 113:316-22
21. Weller PF, Corey EJ, Austen KF, Lewis RA. 1986. Inhibition of homogeneous human eosinophil arylsulfatase B by sulfidopeptide leukotrienes. J. Biol. Chem. 261:1737-44
22. Jakschik BA, Falkenhein S, Parker CW. 1977. Precursor role of arachidonic acid in release of slow reacting substance from rat basophilic leukemia cells. Proc. Natl. Acad. Sci. USA 74:4577-81
23. Lewis RA, Wasserman SI, Goetzl EJ, Austen KF. 1974. Formation of slow-reacting substance of anaphylaxis in human lung tissue and cells before release. J. Exp. Med. 140:1133-46
24. 4 by human eosinophils. J. Biol. Chem. 264:12885-89
25. 2 on pulmonary mechanics in the guinea pig. J. Clin. Invest. 53:1679-85
26. Marfat A, Corey EJ. 1985. Synthesis and structure elucidation of leukotrienes. In Advances in Prostaglandin, Thromboxane, and Leukotriene Research, ed. JE Pike, DR Morton Jr, 14:155-228. New York: Raven
27. Lewis RA, Austen KF, Drazen JM, Clark DA, Marfat A, Corey EJ. 1980. Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc. Natl. Acad. Sci. USA 77:3710-14
28. Morris HR, Taylor GW, Piper PJ, Samhoun MN, Tippins JR. 1980. Slow reacting substances (SRSs); the structure identification of SRSs from rat basophil leukemia (RBL-1) cells. Prostaglandins 19:185-201
29. Lewis RA, Drazen JM, Austen KF, Clark DA, Corey EJ. 1980. Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. Biochem. Biophys. Res. Commun. 96:271-77
30. 4-induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors. Proc. Natl. Acad. Sci. USA 81:4922-25
31. Drazen JM, Austen KF, Lewis RA, Clark DA, Goto G, et al. 1980. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc. Natl. Acad. Sci. USA 77:4354-58
32. 4 diastereoisomers and the subclass-specific S-diastereoisomeric sulfoxides. J. Biol. Chem. 258:15004-10
33. 4 synthetase of rat basophilic leukemia cells. Proc. Natl. Acad. Sci. USA 82:8399-403
34. 4 synthase of guinea pig lung. J. Clin. Invest. 81:866-71
35. 4 synthase. Proc. Natl. Acad. Sci. USA 89:11603-6
36. 4. Proc. Natl. Acad. Sci. USA 91:7663-67
37. 4 synthase: organization, nucleotide sequence, and chromosomal localization to 5q35. J. Biol. Chem. 271:11356-61
38. 4 synthase. Eur. J. Biochem. 238:606-12
39. 4 synthase. Eur. J. Biochem. 248:807-13
40. 4 synthase expression by interleukin 4. J. Exp. Med. 193:123-33
41. 1R. Proc. Natl. Acad. Sci. USA 100:11589-93
42. 4 synthase. J. Biol. Chem. 272:13923-28
43. 4 synthase at 4.5 Å resolution in projection. Structure 12:2009-14
44. 4 synthase, the membrane protein for cysteinyl leukotriene biosynthesis. Nature 448:609-12
45. 4 synthase. J. Biol. Chem. 276:22608-13
46. Maekawa A, Kanaoka Y, Lam BK, Austen KF. 2001. Identification in mice of two isoforms of the cysteinyl leukotriene 1 receptor that result from alternative splicing. Proc. Natl. Acad. Sci. USA 98:2256-61
47. Maekawa A, Austen KF, Kanaoka Y. 2002. Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J. Biol. Chem. 277:20820-24
48. Beller TC, Maekawa A, Friend DS, Austen KF, Kanaoka Y. 2004. Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J. Biol. Chem. 44:46129-34
49. Beller TC, Friend DS, Maekawa A, Lam BK, Austen KF, Kanaoka Y. 2004. Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc. Natl. Acad. Sci. USA 101:3047-52
50. Caulfield JP, Lewis RA, Hein A, Austen KF. 1980. Secretion in dissociated human pulmonary mast cells: evidence for solubilization of granule contents before discharge. J. Cell Biol. 85:299-312
51. Schwartz LB, Riedel C, Caulfield JP, Wasserman SI, Austen KF. 1981. Cell association of complexes of chymase, heparin proteoglycan, and protein after degranulation by rat mast cells. J. Immunol. 126:2071-78
52. Schwartz LB, Lewis RA, Austen KF. 1981. Tryptase from human pulmonary mast cells. Purification and characterization. J. Biol. Chem. 256:11939-43
53. Schwartz LB, Kawahara MS, Hugh TE, Vik D, Fearon DT, Austen KF. 1983. Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. J. Immunol. 130:1891-95
54. Reynolds DS, Gurley DS, Stevens RL, Sugarbaker DJ, Austen KF, Serafin WE. 1989. Cloning of cDNAs that encode human mast cell carboxypeptidase A, and comparison of the protein with mouse mast cell carboxypeptidase A and rat pancreatic carboxypeptidases. Proc. Natl. Acad. Sci. USA 86:9480-84
55. Reynolds DS, Gurley DS, Austen KF. 1992. Cloning and characterization of the novel gene for mast cell carboxypeptidase A. J. Clin. Invest. 89:273-82
56. Schneider LA, Schlenner SM, Feyerabend TB, Wunderlin M, Rodewald H-R. 2007. Molecular mechanism of mast cell-mediated defense against endothelial and snake venom sarafotoxin. J. Exp. Med. 204:2629-39
57. Reynolds DS, Serafin WE, Faller DV, Wall DA, Abbas AK, et al. 1988. Immortalization of murine connective tissue-type mast cells at multiple stages of their differentiation by coculture of splenocytes with fibroblasts that produce Kirsten sarcoma virus. J. Biol. Chem. 263:12783-91
58. Reynolds DS, Stevens RL, Gurley DS, Lane WS, Austen KF, Serafin WE. 1989. Isolation and molecular cloning of mast cell carboxypeptidase A. J. Biol. Chem. 264:20094-99
59. Reynolds DS, Stevens RL, Lane WS, Carr MH, Austen KF, Serafin WE. 1990. Different mouse mast cell populations express various combinations of at least six distinct mast cell serine proteases. Proc. Natl. Acad. Sci. USA 87:3230-34
60. Serafin WE, Reynolds DS, Rogelj S, Lane WS, Conder GA, et al. 1990. Identification and molecular cloning of a novel mouse mucosal mast cell serine protease. J. Biol. Chem. 265:423-29
61. Serafin WE, Sullivan TP, Conder GA, Ebrahimi A, Marcham P, et al. 1991. Cloning of the cDNA and gene for mouse mast cell protease 4: demonstration of its late transcription in mast cell subclasses and analysis of its homology to subclass-specific neutral proteases of the mouse and rat. J. Biol. Chem. 266:1934-41
62. McNeil HP, Austen KF, Somerville LL, Gurish MF, Stevens RL. 1991. Molecular cloning of the mouse mast cell protease-5 gene: a novel secretory granule protease expressed early in the differentiation of serosal mast cells. J. Biol. Chem. 266:20316-22
63. Reynolds DS, Gurley DS, Austen KF, Serafin WE. 1991. Cloning of the cDNA and gene of mouse mast cell protease-6: transcription by progenitor mast cells and mast cells of the connective tissue subclass. J. Biol. Chem. 266:3847-53
64. Hunt JE, Stevens RL, Austen KF, Zhang J, Xia Z, Ghildyal N. 1996. Natural disruption of the mouse mast cell protease 7 gene in the C57BL/6 mouse. J. Biol. Chem. 271:2851-55
65. Hunt JE, Friend DS, Gurish MF, Feyfant E, Sali A, et al. 1997. Mouse mast cell protease 9, a novel member of the chromosome 14 family of serine proteases that is selectively expressed in uterine mast cells. J. Biol. Chem. 272:29158-66
66. Gurish MF, Ghildyal N, McNeil HP, Austen KF, Gillis S, Stevens RL. 1992. Differential expression of secretory granule proteases in mouse mast cells exposed to interleukin 3 and c-kit ligand. J. Exp. Med. 175:1003-12
67. Ghildyal N, Friend DS, Nicodemus CF, Austen KF, Stevens RL. 1993. Reversible expression of mouse mast cell protease 2 mRNA and protein in cultured mast cells exposed to interleukin-10. J. Immunol. 151:3206-14
68. Xia Z, Ghildyal N, Austen KF, Stevens RL. 1996. Post-transcriptional regulation of chymase expression in mast cells: a cytokine-dependent mechanism for controlling the expression of granule neutral proteases of hematopoietic cells. J. Biol. Chem. 271:8747-53
69. Friend DS, Ghildyal N, Austen KF, Gurish MF, Matsumoto R, Stevens RL. 1996. Mast cells that reside at different locations in the jejunum of mice infected with Trichinella spiralis exhibit sequential changes in their granule ultrastructure and chymase phenotype. J. Cell Biol. 135:279-90
70. Gurish MF, Pear WS, Stevens RL, Scott ML, Sokol K, et al. 1995. Tissue-regulated differentiation and maturation of a v-abl-immortalized mast cell-committed progenitor. Immunity 3:175-86
71. Yurt RW, Leid RW Jr, Austen KF, Silbert JE. 1977. Native heparin from rat peritoneal mast cells. J. Biol. Chem. 252:518
72. Metcalfe DD, Lewis RA, Silbert JE, Rosenberg RD, Wasserman SI, Austen KF. 1979. Isolation and characterization of heparin from human lung. J. Clin. Invest. 64:1537-43
73. Metcalfe DD, Smith JA, Austen KF, Silbert JA. 1980. Polydispersity of rat mast cell heparin. Implications for proteoglycan assembly. J. Biol. Chem. 255:11753-58
74. Razin E, Stevens RL, Akiyama F, Schmid K, Austen KF. 1982. Culture from mouse bone marrow of a subclass of mast cells possessing a distinct chondroitin sulfate proteoglycan with glycosaminoglycans rich in N-acerylgalactosamine-4,6- disulfate. J. Biol. Chem. 257:7229-36
75. 3H] diisopropyl fluorophosphate-binding proteins are exocytosed from activated mouse bone marrow-derived mast cells. J. Biol. Chem. 261:15017-21
76. Avraham S, Stevens RL, Gartner MC, Austen KF, Lalley PA, Weis JH. 1988. Isolation of a cDNA that encodes the peptide core of the secretory granule proteoglycan of rat basophilic leukemia-1 cells and assessment of its homology to the human analogue. J. Biol. Chem. 263:7292-96
77. Stevens RL, Avraham S, Gartner MC, Bruns GAP, Austen KF, Weis JH. 1988. Isolation and characterization of a cDNA that encodes the peptide core of the secretory granule proteoglycan of human promyelocytic leukemia HL-60 cells. J. Biol. Chem. 263:7287-91
78. Avraham S, Austen KF, Nicodemus CF, Gartner MC, Stevens RL. 1989. Cloning and characterization of the mouse gene that encodes the peptide core of secretory granule proteoglycans and expression of this gene in transfected rat-1 fibroblasts. J. Biol. Chem. 264:16719-26
79. Kitamura Y, Go S, Hatanaka K. 1978. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 52:447-52
80. Rodewald HR, Dessing M, Dvorak AM, Galli SJ. 1996. Identification of a committed precursor for the mast cell lineage. Science 271:818-22
81. Crapper RM, Schrader JW. 1983. Frequency of mast cell precursors in normal tissues determined by an in vitro assay: antigen induces parallel increases in the frequency of P cell precursors and mast cells. J. Immunol. 131:923-28
82. Gurish MF, Tao H, Abonia JP, Arya A, Friend DS, et al. 2001. Intestinal mast cell progenitors require CD49dβ7 (α4β7 integrin) for tissue-specific homing. J. Exp. Med. 194:1243-52
83. Abonia JP, Austen KF, Rollins BJ, Joshi SK, Flavell RA, et al. 2005. Constitutive homing of mast cell progenitors to the intestine depends on autologous expression of the chemokine receptor CXCR2. Blood 105:4308-13
84. Abonia JP, Hallgren J, Jones T, Shi R, Xu Y, et al. 2006. Alpha-4 integrins and VCAM-1, but not MAdCAM-1, are essential for recruitment of mast cell progenitors to the inflamed lung. Blood 108:1588-94
85. Arinobu Y, Iwasaki H, Gurish MF, Mizuno S, Shigematsu H, et al. 2005. Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc. Natl. Acad. Sci. USA 102:18105-10
86. Katz HR, Benson AC, Austen KF. 1989. Activation and phorbol ester-stimulated phosphorylation of a plasma membrane glycoprotein antigen expressed on mouse IL-3-dependent mast cells and serosal mast cells. J. Immunol. 142:919-26
87. Arm JP, Gurish MF, Reynolds DS, Scott HC, Gartner CS, et al. 1991. Molecular cloning of gp49, a cell surface antigen that is preferentially expressed by mouse mast cell progenitors and is a new member of the immunoglobulin superfamily. J. Biol. Chem. 266:15966-73
88. Castells MC, Wu X, Arm JP, Austen KF, Katz HR. 1994. Cloning of the gp49B gene of the immunoglobulin superfamily and demonstration that one of its two products is an early-expressed mast cell surface protein originally described as gp49. J. Biol. Chem. 269:8393-401
89. Katz HR, Vivier E, Castells MC, McCormick MJ, Chambers JM, Austen KF. 1996. Mouse mast cell gp49B1 contains two immunoreceptor tyrosine-based inhibition motifs and suppresses mast cell activation when coligated with the high affinity Fc receptor for IgE. Proc. Natl. Acad. Sci. USA 93:10809-14
90. Daheshia M, Friend DS, Grusby MJ, Austen KF, Katz HR. 2001. Increased severity of local and systemic anaphylactic reactions in gp49B1-deficient mice. J. Exp. Med. 194:227-33
91. Feldweg AM, Friend DS, Zhou JS, Kanaoka Y, Daheshia M, et al. 2003. gp49B1 suppresses stem cell factor-induced mast cell activation-secretion and attendant inflammation in vivo. Eur. J. Immunol. 33:2262-68
92. Zhou JS, Friend DS, Feldweg AM, Daheshia M, Li L, et al. 2003. Prevention of lipopolysaccharide-induced microangiopathy by gp49B1: evidence for an important role for gp49B1 expression on neutrophils. J. Exp. Med. 198:1243-51
93. Arm JP, Nwankwo C, Austen KF. 1997. Molecular identification of a novel family of human Ig superfamily members that possess immunoreceptor tyrosine-based inhibition motifs and homology to the mouse gp49B1 inhibitory receptor. J. Immunol. 159:2342-49
94. Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw AC. 1954. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 120:279-85
95. Fearon DT, Austen KF, Ruddy S. 1973. Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J. Exp. Med. 138:1305-13
96. Fearon DT, Austen KF. 1975. Properdin: binding to C3b and stabilization of the C3b-dependent convertase. J. Exp. Med. 142:856-63
97. Weiler JM, Daha MR, Austen KF, Fearon DT. 1976. Control of the amplification convertase of complement by the plasma protein β1H. Proc. Natl. Acad. Sci. USA 73:3268-72
98. Whaley K, Ruddy S. 1976. Modulation of the alternative complement pathways by beta 1H globulin. J. Exp. Med. 144:1147-63
99. Fearon DT, Austen KF. 1975. Initiation of C3 cleavage in the alternative complement pathway. J. Immunol. 115:1357-61
100. Fearon DT, Austen KF, Ruddy S. 1974. Properdin factor D: characterization of its active site and isolation of the precursor form. J. Exp. Med. 139:355-66
101. Fearon DT, Austen KF. 1977. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc. Natl. Acad. Sci. USA 74:1683-87
102. Fearon DT, Austen KF. 1977. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J. Exp. Med. 146:22-33
103. Fearon DT. 1978. Regulation by membrane sialic acid of beta 1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc. Natl. Acad. Sci. USA 75:1971-75
104. 4) in human skin. J. Invest. Dermatol. 80:115-19
105. Weiss JW, Drazen JM, Coles N, McFadden ER Jr, Weller PF, et al. 1982. Bronchoconstrictor effects of leukotriene C in humans. Science 216:196-98
106. Griffin M, Weiss JW, Leitch AG, McFadden ER Jr, Corey EJ, et al. 1983. Effects of leukotriene D on the airways in asthma. N. Engl. J. Med. 308:436-39
107. 4 in normal and asthmatic individuals. Am. Rev. Respir. Dis. 135:333-37
108. Sheffer AL, Austen KF. 1980. Exercise-induced anaphylaxis. J. Allergy Clin. Immunol. 66:106-11
109. Sheffer AL, Soter NA, McFadden ER Jr, Austen KF. 1983. Exercise-induced anaphylaxis: a distinct form of physical allergy. J. Allergy Clin. Immunol. 71:311-16
110. Sheffer AL, Tong AKF, Murphy GF, Lewis RA, McFadden ER Jr, Austen KF. 1985. Exercise-induced anaphylaxis: a serious form of physical allergy associated with mast cell degranulation. J. Allergy Clin. Immunol. 75:479-84
111. Soter NA, Wasserman SI, Austen KF, McFadden ER Jr. 1980. Release of mast cell mediators and alterations in lung function in patients with cholinergic urticaria. N. Engl. J. Med. 302:604-8
112. Roberts LJ II, Lewis RA, Oates JA, Austen KF. 1979. Prostaglandin, thromboxane, and 12-hydroxy-5,8,10,14-eicosatetraenoic acid production by ionophore-stimulated rat serosal mast cells. Biochim. Biophys. Acta 575:185-92
113. 2 generation after activation of rat and human mast cells with anti-IgE. J. Immunol. 129:1627-31
114. 2 in patients with systemic mastocytosis. N. Engl. J. Med. 303:1400-4
115. Soter NA, Austen KF, Wasserman SI. 1979. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N. Engl. J. Med. 301:465-69
116. Donaldson VH, Evans RR. 1963. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C'1-esterase. Am. J. Med. 35:37-44
117. Austen KF, Sheffer AL. 1965. Detection of hereditary angioneurotic edema by demonstration of a profound reduction in the second component of human complement. N. Engl. J. Med. 272:649-56
118. gp and functionally pure human second component. J. Immunol. 99:1162-72
119. Spaulding WB. 1955. Hereditary angioneurotic oedema in two families. Can. Med. Assoc. J. 73:181-87
120. Sheffer AL, Fearon DT, Austen KF. 1979. Clinical and biochemical effects of impeded androgen (oxymethalone) therapy of hereditary angioedema (HAE). J. Allergy Clin. Immunol. 64:275-80
121. Sheffer AL, Fearon DT, Austen KF. 1981. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J. Allergy Clin. Immunol. 68:181-87
122. Caldwell JR, Ruddy S, Schur PH, Austen KF. 1972. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin. Immunol. Immunopathol. 1:39
123. Geha RS, Quinti I, Austen KF, Cicardi M, Sheffer A, Rosen FS. 1985. Acquired C1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins. N Engl. J. Med. 312:534-40
124. Fearon DT. 1980. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J. Exp. Med. 152:20-30
125. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF. 1982. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J. Immunol. 129:184-89
126. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF. 1983. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc. Natl. Acad. Sci. USA 80:5066-70
127. Hunsicker LG, Ruddy S, Carpenter CB, Schur PH, Merrill JP, et al. 1972. Metabolism of third complement component (C3) in nephritis: role of the classical and alternate (properdin) pathways for complement activation. N. Engl. J. Med. 287:835-40
128. Daha MR, Fearon DT, Austen KF. 1976. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J. Immunol. 116:1-7
129. Daha MR, Austen KF, Fearon DT. 1977. The incorporation of C3 nephritic factor (C3NeF) into a stabilized C3 convertase, C3b, Bb (C3NeF) and its release after decay of convertase function. J. Immunol. 19:812-17
130. Daha MR, Austen KF, Fearon DT. 1978. Heterogeneity, polypeptide composition and antigenic reactivity of C3NeF. J. Immunol. 120:1389-94
131. Austen KF. 2004. Acceptance of the Kober Medal: It only gets better. J. Clin. Invest. 114:1177